Post by
kalman007 on Oct 19, 2021 1:54pm
NASDAQ
I would agree that this company needs the exposure of larger indexes. Hopefully we shareholders won't get beat up in the process. At the current share price resulting in an enterprise value of only 80 million is a fraction of what the potential upside could be given the success of PMN310. It's been too long and it seems that deadlines have come and go over the years. I for one am growing very impatient with Eugene and would like to see concrete strategies to reward it's loyal stakeholders.
Comment by
Thenorth1990 on Oct 19, 2021 2:06pm
Nasdaq move is one of those rare times when this management have kept their promise. Announced in March as a priority and already seeing some progress is encouraging and I hope they stick to their other major commitments as well.
Comment by
Mole101 on Oct 19, 2021 3:30pm
I'll have to disagree with the Nasdaq wishful thinking , Just because a company does a reverse split and says it's going to the Nasdaq it doesn't mean that's going to end there .. I believe consolidation it's happening to make the company more attractive to prospective investors and future pp races .. I owen planet you of shares a d I don't buy it..
Comment by
Thenorth1990 on Oct 19, 2021 4:37pm
I fully agree with you but I see this a sign of more control of Boston group , we will see further dilution with another year of being in Nasdaq , unless we generate enough from serology to fund our other operations and I am not that optimistic about revenue from serolgy . It might generate some revenue but not enough to save us from future pp